Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q3 2015 · 10-Q
Revenue$24.18M$24.18M+1,214.1% vs Q3 2014 Net Income$5.59M$5.59MN/M vs Q3 2014 EPS Diluted$0.07$0.07N/M vs Q3 2014 Operating Income$3,730,417N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$14,642,380N/M Margins · derivedOperating margin15.4%+468.1 pt vs Q3 2014
Net margin23.1%+413.1 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end